1. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism 
Masafumi Fukagawa, Ryutaro Shimazaki, Tadao Akizawa 
Kidney International 
Volume 94, Issue 4, Pages (October 2018)
DOI: /j.kint
Copyright © 2018 International Society of Nephrology Terms and Conditions

2. Kidney International 2018 94, 818-825DOI: (10.1016/j.kint.2018.05.013)
Copyright © 2018 International Society of Nephrology Terms and Conditions

3. Figure 1 Patient disposition.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

4. Figure 2
Changes in (a) intact parathyroid hormone (iPTH), (b) whole PTH, (c) serum-ionized calcium, (d) serum-corrected calcium, (e) serum phosphorus, and (f) intact fibroblast growth factor 23 (FGF23). Levels (median with 25th and 75th percentiles) of iPTH, whole PTH, serum-ionized calcium, serum-corrected calcium, phosphorus, and intact FGF23 decreased over time in both groups after study drug administration.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

5. Figure 3
Forest plot of gastrointestinal-related adverse events. The overall incidence of gastrointestinal-related adverse events (nausea, vomiting, abdominal discomfort, decreased appetite, and abdominal distension) was lower in the evocalcet group than in the cinacalcet group. CI, confidence interval.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions

6. Figure 4
Study design. iPTH, intact parathyroid hormone. aPatients with prior cinacalcet treatment. bMeasured at 1 week before the initiation of study treatment, which was measured during screening.
Kidney International  , DOI: ( /j.kint )
Copyright © 2018 International Society of Nephrology Terms and Conditions